GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mersana Therapeutics Inc (STU:0M4) » Definitions » Accounts Payable

Mersana Therapeutics (STU:0M4) Accounts Payable : €1.83 Mil (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Mersana Therapeutics Accounts Payable?

Mersana Therapeutics's Accounts Payable for the quarter that ended in Sep. 2024 was €1.83 Mil.

Mersana Therapeutics's quarterly Accounts Payable declined from Mar. 2024 (€2.84 Mil) to Jun. 2024 (€2.80 Mil) and declined from Jun. 2024 (€2.80 Mil) to Sep. 2024 (€1.83 Mil).

Mersana Therapeutics's annual Accounts Payable increased from Dec. 2021 (€10.90 Mil) to Dec. 2022 (€13.17 Mil) but then declined from Dec. 2022 (€13.17 Mil) to Dec. 2023 (€6.71 Mil).


Mersana Therapeutics Accounts Payable Historical Data

The historical data trend for Mersana Therapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mersana Therapeutics Accounts Payable Chart

Mersana Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accounts Payable
Get a 7-Day Free Trial Premium Member Only 6.57 6.86 10.90 13.17 6.71

Mersana Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.13 6.71 2.84 2.80 1.83

Mersana Therapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.


Mersana Therapeutics Accounts Payable Related Terms

Thank you for viewing the detailed overview of Mersana Therapeutics's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


Mersana Therapeutics Business Description

Traded in Other Exchanges
Address
840 Memorial Drive, Cambridge, MA, USA, 02139
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.

Mersana Therapeutics Headlines

No Headlines